Literature DB >> 2440994

Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue.

H Godridge, G P Reynolds, C Czudek, N A Calcutt, M Benton.   

Abstract

Brain tissue taken at necropsy from five cases of Down's syndrome and six controls was analysed for changes in neurotransmitter markers. Concentrations of noradrenaline (NA), dopamine (DA) and its major metabolite homovanillic acid (HVA), 5-hydroxytryptamine (5HT) and its metabolite 5-hydroxyindoleacetic acid (5HIAA) were determined by means of HPLC, whilst choline acetyltransferase (ChAT) was measured by a radiochemical technique. Significant reductions in NA, 5HT and ChAT were found in most cortical and subcortical regions of the Down's syndrome tissue investigated. The neuropathological lesions were assessed using a fluorescent stain for neuritic plaques and neurofibrillary tangles. These were present to varying extents in every Down's syndrome case except the youngest but were not found in control tissue of comparable age. The results indicate profound transmitter deficits and neuropathological abnormalities in adult patients with Down's syndrome, which closely resemble those of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440994      PMCID: PMC1032086          DOI: 10.1136/jnnp.50.6.775

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Presenile dementia and Alzheimer's disease in mongolism.

Authors:  M I Olson; C M Shaw
Journal:  Brain       Date:  1969-03       Impact factor: 13.501

2.  Presenile dementia in Down's syndrome. Ultrastructural identity with Alzheimer's disease.

Authors:  W G Ellis; J R McCulloch; C L Corley
Journal:  Neurology       Date:  1974-02       Impact factor: 9.910

3.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

4.  Serotonin nerve cells in Alzheimer's disease.

Authors:  D M Mann; P O Yates
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-01       Impact factor: 10.154

5.  Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia.

Authors:  G P Reynolds
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

Review 6.  Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature.

Authors:  R Adolfsson; C G Gottfries; B E Roos; B Winblad
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

7.  Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome.

Authors:  C M Yates; J Simpson; A Gordon; A F Maloney; Y Allison; I M Ritchie; A Urquhart
Journal:  Brain Res       Date:  1983-11-28       Impact factor: 3.252

8.  The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome.

Authors:  P C Burger; F S Vogel
Journal:  Am J Pathol       Date:  1973-11       Impact factor: 4.307

9.  Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.

Authors:  D M Bowen; S J Allen; J S Benton; M J Goodhardt; E A Haan; A M Palmer; N R Sims; C C Smith; J A Spillane; M M Esiri; D Neary; J S Snowdon; G K Wilcock; A N Davison
Journal:  J Neurochem       Date:  1983-07       Impact factor: 5.372

10.  Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.

Authors:  D R Tomlinson; R J Moriarty; J H Mayer
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

View more
  23 in total

1.  Amyloid precursor protein metabolism in fibroblasts from individuals with one, two or three copies of the amyloid precursor protein (APP) gene.

Authors:  M Racchi; J A Johnston; F M Flood; R F Cowburn; S Govoni
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

2.  Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.

Authors:  Gurjinder Kaur; Ajay Sharma; Wenjin Xu; Scott Gerum; Melissa J Alldred; Shivakumar Subbanna; Balapal S Basavarajappa; Monika Pawlik; Masuo Ohno; Stephen D Ginsberg; Donald A Wilson; David N Guilfoyle; Efrat Levy
Journal:  J Neurosci       Date:  2014-04-09       Impact factor: 6.167

Review 3.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

4.  A pathological study of the association between Lewy body disease and Alzheimer's disease.

Authors:  W R Gibb; C Q Mountjoy; D M Mann; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 5.  On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome.

Authors:  Alberto C S Costa
Journal:  Dev Neurosci       Date:  2011-09-02       Impact factor: 2.984

6.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

7.  Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model.

Authors:  William J Netzer; Craig Powell; Yi Nong; Jacqueline Blundell; Lili Wong; Karen Duff; Marc Flajolet; Paul Greengard
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

Review 8.  The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases.

Authors:  Antonio Contestabile; Elisabetta Ciani; Andrea Contestabile
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

9.  Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.

Authors:  P Vieregge; G Ziemens; M Freudenberg; A Piosinski; A Muysers; B Schulze
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

10.  Evidence for a membrane defect in Alzheimer disease brain.

Authors:  R M Nitsch; J K Blusztajn; A G Pittas; B E Slack; J H Growdon; R J Wurtman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.